Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines.

Future medicinal chemistry - 1 Apr 2018

Dayal Neetu, Opoku-Temeng Clement, Hernandez Delmis E, Sooreshjani Moloud Aflaki, Carter-Cooper Brandon A, Lapidus Rena G, Sintim Herman O

Abstract excerpt

AIM: Approximately 30% of acute myeloid leukemia (AML) patients carry FLT3 tyrosine kinase domain (TKD) mutations or internal tandem duplication (FLT3-ITD). Currently there is a paucity of compounds that are active against drug-resistant FLT3-ITD, which contains secondary mutations in the TKD, mainly at residues D835/F691. RESULTS: HSD1169, a novel compound, is active against FLT3-ITD (D835 or F691). HSD1169 is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to fms-Like Tyrosine Kinase 3

Share to G1 Phase

Share to Leukemia, Myeloid, Acute

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 29437468
DOI: 10.4155/fmc-2017-0298
PMCID: PMC6367750

Genes

FLT3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines.PMID 29437468Read ↗

TP-0903 is active in models of drug-resistant acute myeloid leukemia.Semantic proximity Read ↗

Inhibition of FLT3 in AML: a focus on sorafenib.Semantic proximity Read ↗

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.Semantic proximity Read ↗

An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L.Semantic proximity Read ↗

CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells.Semantic proximity Read ↗

T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.Semantic proximity Read ↗

Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736Semantic proximity Read ↗

Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.Semantic proximity Read ↗

Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach.Semantic proximity Read ↗

An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Discovery of indirubin-3'-aminooxy-acetamide derivatives as potent and selective FLT3/D835Y mutant kinase inhibitors for acute myeloid leukemia.Semantic proximity Read ↗

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.